Overweight Clinical Trial
Official title:
The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation
Verified date | February 2017 |
Source | Hvidovre University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to determine the type of macronutrient (carbohydrate, lipid or protein) that most potently stimulates the endogen secretion of different gut hormones (primary outcome = Glucagon-Like peptide-1) in gastric bypass operated patients. The study also includes a comparison of the secretion of gut hormones after oral intake of lipid with or without a pancreatic lipase inhibitor.
Status | Active, not recruiting |
Enrollment | 18 |
Est. completion date | June 2017 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 55 Years |
Eligibility |
RYGB Patients: Inclusion Criteria: - Underwent RYGB surgery more than 18 months earlier, weight stabile (+/- 5 kg during 1 month) Exclusion Criteria: - Inadequate thyroid substitution, undergoing treatment with drugs known to interact with Orlistat (such as cyclosporine, anticoagulating agents, amiodarone, amlodipine and epileptics), where pausing the treatment with these is not an option. Type 1 or 2 diabetes mellitus now or prior to RYGB operation. Serious heart or respiratory illness. Haemoglobin levels below 6,5 mM. Healthy control subjects: Inclusion Criteria: - Have not underwent bariatric surgery. Exclusion Criteria: - Inadequate thyroid substitution, undergoing treatment with drugs known to interact with Orlistat (such as cyclosporine, anticoagulating agents, amiodarone, amlodipine and epileptics), where pausing the treatment with these is not an option. Type 1 or 2 diabetes mellitus now or prior. Serious heart or respiratory illness. Haemoglobin levels below 6,5 mM. |
Country | Name | City | State |
---|---|---|---|
Denmark | Endocrinology Research Center, Hvidovre University Hospital | Hvidovre | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Kirstine Nyvold Bojsen-Moeller | University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Between groups difference in Glucagon-like Peptide 1 secretion (evaluated by iAUC). | I.e. Comparison of GLP-1 secretion (iAUC) as a result of intake of different macronutrients between Gastric bypass operated patients and Healthy volunteers. | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | |
Other | Between groups difference in Glucagon secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Glucose-dependent insulinotropic peptide secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Cholecystokinin secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Peptide YY 3-36 secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Ghrelin secretion (evaluated by iAUC). | 0, 30, 45, 60, 120, 180, 240 | ||
Other | Between groups difference in Changes in bile acids. | 0, 30, 45, 60, 120, 180, 240 | ||
Other | Between groups difference in Changes in glycerol, triacylglycerol and free fatty acids. | 0, 30, 45, 60, 120, 180, 240 | ||
Other | Between groups difference in Insulin secretion (evaluated by iAUC). | 2xBasline, 0, 10, 15, 20, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Plasma glucose concentration. | 2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Visual Analog Scale. | Hunger, satiety, abdominal pain and nausea measured by standard 10 cm Visual Analog Scale | 0, 30, 60, 90, 120, 180, 240 | |
Other | Between groups difference in Ad libitum food intake (grams). | 240 | ||
Other | Between groups difference in Heart rate (bpm). | 2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Other | Between groups difference in Blood pressure (mmhg). | 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Primary | Within group difference in Glucagon-like Peptide 1 secretion (evaluated by iAUC). | I.e. Comparison of GLP-1 secretion (iAUC) as a result of intake of different macronutrients between a) gastric bypass patients only b) healthy volunteers only. | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | |
Secondary | Within group difference in Glucagon secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Glucose-dependent insulinotropic peptide secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Cholecystokinin secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Peptide YY 3-36 secretion (evaluated by iAUC). | Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Ghrelin secretion (evaluated by iAUC). | 0, 30, 45, 60, 120, 180, 240 | ||
Secondary | Within group difference in Changes in bile acids. | 0, 30, 45, 60, 120, 180, 240 | ||
Secondary | Within group difference in Changes in glycerol, triacylglycerol and free fatty acids. | 0, 30, 45, 60, 120, 180, 240 | ||
Secondary | Within group difference in Insulin secretion (evaluated by iAUC). | 2xBasline, 0, 10, 15, 20, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Plasma glucose concentration. | 2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Visual Analog Scale. | Hunger, satiety, abdominal pain and nausea measured by standard 10 cm Visual Analog Scale | 0, 30, 60, 90, 120, 180, 240 | |
Secondary | Within group difference in Ad libitum food intake (grams). | 240 | ||
Secondary | Within group difference in Heart rate (bpm). | 2xBasline, 0, 5, 10, 15, 20, 25, 30, 40, 45, 60, 90, 120, 180, 240 | ||
Secondary | Within group difference in Blood pressure (mmhg). | 0, 15, 30, 45, 60, 90, 120, 180, 240 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 | |
Completed |
NCT02899390 -
Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes
|
N/A |